Cargando…

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future

In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no longer available. Prognosis and survival of pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stueven, Anna Kathrin, Kayser, Antonin, Wetz, Christoph, Amthauer, Holger, Wree, Alexander, Tacke, Frank, Wiedenmann, Bertram, Roderburg, Christoph, Jann, Henning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627451/ https://www.ncbi.nlm.nih.gov/pubmed/31234481 http://dx.doi.org/10.3390/ijms20123049

Ejemplares similares

Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?
por: Wetz, Christoph, et al.
Publicado: (2020)

Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review
por: Özdirik, Burcin, et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies
por: Özdirik, Burcin, et al.
Publicado: (2020)

A case report of an excellent response to interferon- α in a patient with functional metastasized neuroendocrine tumor refractory to other treatments
por: Özdirik, Burcin, et al.
Publicado: (2020)

Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study
por: Özdirik, Burcin, et al.
Publicado: (2020)

PD-L1 – inhibitors in neuroendocrine neoplasia: Results from a real-life study
por: Özdirik, Burcin, et al.
Publicado: (2021)

Osteopontin is a prognostic circulating biomarker in patients with neuroendocrine neoplasms
por: Kidess, Evelyn, et al.
Publicado: (2023)

A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report
por: Özdirik, Burcin, et al.
Publicado: (2021)

The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors
por: Geisler, Lukas, et al.
Publicado: (2021)

Serum levels of miR-223 but not miR-21 are decreased in patients with neuroendocrine tumors
por: Hellberg, Teresa, et al.
Publicado: (2020)

Inflammatory Cytokines Associated with Diagnosis, Tumor Grade and Prognosis in Patients with Neuroendocrine Tumors
por: Geisler, Lukas, et al.
Publicado: (2022)

Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [(177)Lu]Lu-DOTATOC
por: Galler, Markus, et al.
Publicado: (2022)

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
por: Ambrosini, Valentina, et al.
Publicado: (2022)

The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [(177)Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis
por: Ruhwedel, Tristan, et al.
Publicado: (2021)

Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms
por: Detjen, Katharina M., et al.
Publicado: (2021)

Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
por: Watanabe, Hirofumi, et al.
Publicado: (2022)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [(18)F]SiTATE
por: Eschbach, Ralf S., et al.
Publicado: (2023)

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
por: Kiesewetter, B., et al.
Publicado: (2022)

The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE
por: Wetz, Christoph, et al.
Publicado: (2019)

Distribution of gastrointestinal neuroendocrine tumors in Europe: results from a retrospective cross-sectional study
por: Loosen, Sven H., et al.
Publicado: (2022)

Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors
por: Ge, Wenhao, et al.
Publicado: (2018)

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2019)

Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies
por: Roderburg, Christoph, et al.
Publicado: (2020)

The role of the innate immune system in the development and treatment of hepatocellular carcinoma
por: Roderburg, Christoph, et al.
Publicado: (2020)

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
por: Appetecchia, Marialuisa, et al.
Publicado: (2010)

The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells
por: Li, Su-Chen, et al.
Publicado: (2012)

Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors
por: Gabrielsen, Jordan, et al.
Publicado: (2019)

Correction: Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2020)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
por: Rustgi, Sheila D., et al.
Publicado: (2021)

Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors
por: Sebastian-Valles, Fernando, et al.
Publicado: (2023)

Automatized Hepatic Tumor Volume Analysis of Neuroendocrine Liver Metastases by Gd-EOB MRI—A Deep-Learning Model to Support Multidisciplinary Cancer Conference Decision-Making
por: Fehrenbach, Uli, et al.
Publicado: (2021)

Analyses of sex-based clinicopathological differences among patients with gastrointestinal neuroendocrine neoplasms in Europe
por: Jann, Henning, et al.
Publicado: (2023)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
por: Ström, Torbjörn, et al.
Publicado: (2019)

Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience
por: Filice, A., et al.
Publicado: (2012)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
por: Saksis, Rihards, et al.
Publicado: (2023)

Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy
por: Loosen, Sven H., et al.
Publicado: (2022)

SAT-LB24 Association of Expression of Somatostatin Receptor 2 Subtype in Non-Pituitary Neuroendocrine Tumors With Response to Treatment With Somatostatin Analogues
por: Siddiqui, Abdullah, et al.
Publicado: (2020)

In Vivo Models for Cholangiocarcinoma—What Can We Learn for Human Disease?
por: Mohr, Raphael, et al.
Publicado: (2020)

Distinct mechanisms of hypoglycaemia in patients with somatostatin‐secreting neuroendocrine tumours
por: Wiesli, Peter, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bvvojshhsslt9tdm3rec0fisgq